Here is a recent BioFlash podcast, in which Kalobios (KBIO) CEO Cameron Durrant provided an update on the development plans for benznidazole and had some interesting...
Read More
This morning the FDA announced its approval of eteplirsen (brand name, Exonys 51) for the treatment of Duchenne muscular dystrophy (DMD) in boys “who have a...
Read MoreThis is a belated examination of an August 24th Forbes interview with the head of R&D at Turing Pharmaceuticals, Dr. Eliseo Salinas. Clearly Dr. Salinas is...
Read MoreThe peer-reviewed results of the aducanumab phase 1B study in prodromal and mild AD are now available in Nature. And while some media outlets are touting this...
Read More
Before the Senate Committee on Aging, former general counsel and senior business executive of Turing Pharmaceuticals, Howard Dorfman, testified today that the closed...
Read More
“When Turing acquired Daraprim®, it also assumed the distribution channels, organizational decisions, and contracts that its predecessor, Impax, had put in place....
Read More